Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: statistical analysis plan for a randomised controlled trial (UPGRADE trial)
Abstract Background Approximately 8–15% of patients undergoing bariatric surgery develop symptomatic gallstone disease within 24 months after surgery. Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery. The aim of the...
Main Authors: | Sylke Haal, Maimoena S. S. Guman, L. Maurits de Brauw, Ruben N. van Veen, Ruben Schouten, Paul Fockens, Victor E. A. Gerdes, Marcel G. W. Dijkgraaf, Rogier P. Voermans |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-020-04605-7 |
Similar Items
-
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial)
by: Thomas C. C. Boerlage, et al.
Published: (2017-12-01) -
Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
by: Alexander V. Smirnov, et al.
Published: (2021-07-01) -
Gallstone Formation Follows a Different Trajectory in Bariatric Patients Compared to Nonbariatric Patients
by: Sylke Haal, et al.
Published: (2021-10-01) -
Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid
by: Nahum Méndez-Sánchez, et al.
Published: (2002-04-01) -
Indications for Laparoscopic Cholecystectomy or Oral Dissolution Therapy with Ursodeoxycholic Acid in Symptomatic Gallstone Disease
by: Andrea Cariati, et al.
Published: (2014-06-01)